China's Simcere Beats Out Eisai In Iguratimod Approval For Rheumatoid Arthritis
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI- China's State FDA cleared Simcere Pharmaceutical Group's new drug application for Iremod (iguratimod) for rheumatoid arthritis, in the world's first approval of the compound, Simcere announced Aug. 25